NDC 67296-2173-03 - Buprenorphine
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 67296-2173
- Requested NDC
- 67296-2173-03
- Package NDCs from labels
- 67296-2173-3, 67296-2173-03
- Manufacturer
- Redpharm Drug
- Effective date
- 2025-12-02
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Buprenorphine - Redpharm Drug | Redpharm Drug | 2025-12-02 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 67296-2173-3 | Buprenorphine | 30 in 1 BOTTLE | TABLET | 30 | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Caldesene Baby | STARCH, CORN AND ZINC OXIDE | Insight Pharmaceuticals LLC | 9f12dee2-7afa-45e9-a729-0fd42bb77715 | 2026-04-22 | Warnings | O8232NY3SJ |
| Caldesene Medicated Protecting | CORNSTARCH AND ZINC OXIDE | Insight Pharmaceuticals LLC | ffc92a0f-a7cf-4a46-b2f1-089df2bbb96b | 2026-04-22 | Warnings | O8232NY3SJ |
| Mannitol | MANNITOL | Hospira, Inc. | 8ad3145e-00e7-4412-b9a5-06f00f264f30 | 2026-04-21 | Warnings, Adverse reactions | 3OWL53L36A |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Bryant Ranch Prepack | 63aaa6cc-8574-4990-8239-6fdeffce92c8 | 2026-04-16 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Unit Dose Solutions, Inc. | 4f979409-f9a2-d3a2-e063-6394a90accd0 | 2026-04-16 | Warnings, Adverse reactions | 56W8MW3EN1 |
| CLENPIQ | SODIUM PICOSULFATE, MAGNESIUM OXIDE, AND ANHYDROUS CITRIC ACID | Ferring Pharmaceuticals Inc. | e95fff66-4ec0-4001-a727-33e66a5ec7d5 | 2026-04-15 | Warnings, Adverse reactions | XF417D3PSL |
| FreshKote Preservative Free Lubricant Eye Drops | POVIDONE, POLYVINYL ALCOHOL | Eyevance Pharmaceuticals | f51c50c3-43ae-4169-9d2b-22b239461dd1 | 2026-04-08 | Warnings | FZ989GH94E |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Aveva Drug Delivery Systems Inc. | cb112448-49a1-4209-bcdb-7cfae6501f51 | 2026-04-07 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Sodium Citrate and Citric Acid | SODIUM CITRATE AND CITRIC ACID | Chartwell Governmental & Specialty RX, LLC | 58c24504-47de-487a-ab8d-18add155ea95 | 2026-04-07 | Adverse reactions | 1Q73Q2JULR |
| BUPRENORPHINE | BUPRENORPHINE | Bryant Ranch Prepack | cd0a90c6-32cc-4114-8573-86ac85503bdf | 2026-04-03 | Warnings, Adverse reactions | 351264 56W8MW3EN1 |
| Buprenorphine HCl and Naloxone HCl | BUPRENORPHINE AND NALOXONE | Bryant Ranch Prepack | 2aaad1a7-a0fd-4dd5-bb53-03afad8f10b9 | 2026-04-03 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | INGENUS PHARMACEUTICALS, LLC | 4951ec29-609b-4836-b0e4-0d9c1d6ae6fe | 2026-03-23 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine HCl | BUPRENORPHINE HCL | REMEDYREPACK INC. | 69a647c0-bc09-4ee2-aeb3-ef286caf25e5 | 2026-03-23 | Warnings, Adverse reactions | 351265 56W8MW3EN1 |
| Leader Advanced Relief Eye Drops | DEXTRAN 70, POLYETHYLENE GLYCOL 400, POVIDONE, TETRAHYDROZOLINE HCL | Cardinal Health | 5c5d6c13-9b51-48f0-8627-b60b0f707fd3 | 2026-03-12 | Warnings | FZ989GH94E |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Clinical Solutions Wholesale, LLC | 99a5b62f-bc08-44f4-abb8-300520d2162a | 2026-03-06 | Warnings, Adverse reactions | 56W8MW3EN1 |
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Clinical Solutions Wholesale, LLC | 8f2b94dc-f42f-45d5-8274-9e748ec20ef0 | 2026-03-05 | Warnings, Adverse reactions | 56W8MW3EN1 |
| buprenorphine hydrochloride and naloxone hydrochloride dihydrate | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Major Pharmaceuticals | c5fbec69-e7de-44a8-b9fa-0378ae61a9fe | 2026-03-03 | Warnings, Adverse reactions | 56W8MW3EN1 |
| buprenorphine hydrochloride | BUPRENORPHINE HYDROCHLORIDE | PAI Holdings, LLC dba PAI Pharma | 442831cf-9636-433a-9a12-e9a8cd31f72a | 2026-02-28 | Warnings, Adverse reactions | 351265 351264 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | PAI Holdings, LLC dba PAI Pharma | d5b011ef-f1be-47f2-8f8b-07553f36193c | 2026-02-28 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Kidnex IV | GINKGO BILOBA, ALPHA-KETOGLUTARICUM ACIDUM, CITRICUM ACIDUM, FUMARICUM ACIDUM, MALICUM ACIDUM, PYRUVIC ACID, SUCCINICUM ACIDUM, ARGENTUM METALLICUM, AURUM METALLICUM, CUPRUM METALLICUM, GERMANIUM SESQUIOXIDE, MERCURIUS VIVUS, NUX VOMICA, KIDNEY (SUIS), LYMPH NODE (SUIS), NAPHTHOCHINONUM, NATRUM OXALACETICUM, PHOSPHORUS, URINARY BLADDER (SUIS), ACONITICUM ACIDUM, CIS- | Energique, Inc. | 23de6b8e-7622-4ba6-89f7-37bd151687e2 | 2026-02-26 | Warnings | XF417D3PSL |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.